Exhaled Breath Analysis for Prediction of Response to Anti-PD1 Therapy in Patients with NSCLC

被引：0
|
作者：
de Vries, Rianne
Muller, Mirte
Wolf-Lansdorf, Marguerite
Baas, Paul
Sterk, Peter J.
Van den Heuvel, Michel M.
机构：
来源：
EUROPEAN RESPIRATORY JOURNAL | 2017年 / 50卷
关键词：
D O I：
10.1183/1393003.congress-2017.OA1473
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
OA1473
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Electronic Nose: An Early Response Biomarker for Anti-PD1 Therapy in Patients with NSCLC
    Muller, Mirte
    Vries, Rianne
    Sterk, Peter
    Baas, Paul
    Van Den Heuvell, Michael
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1306 - S1307
  • [2] Prediction of response to anti-PD-1 therapy in patients with non-small-cell lung cancer by electronic nose analysis of exhaled breath
    de Vries, R.
    Muller, M.
    van der Noort, V.
    Theelen, W. S. M. E.
    Schouten, R. D.
    Hummelink, K.
    Muller, S. H.
    Wolf-Lansdorf, M.
    Dagelet, J. W. F.
    Monkhorst, K.
    Zee, A. H. Maitland-van der
    Baas, P.
    Sterk, P. J.
    van den Heuvel, M. M.
    [J]. ANNALS OF ONCOLOGY, 2019, 30 (10) : 1660 - 1666
  • [3] Radiomics for Predicting Response to First-Line Anti-PD1 Therapy in Advanced NSCLC
    Ackermann, C.
    Fornacon-Wood, I.
    Tay, R.
    Manoharan, P.
    Price, G.
    Lindsay, C.
    Faivre-Finn, C.
    Blackhall, F.
    Cobben, D.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S457 - S458
  • [4] Prediction of primary resistance to anti-PD1 therapy (APD1) in second-line NSCLC
    Smit, E. F.
    Aerts, J. G.
    Muller, M.
    Niemeijer, A-L. N.
    Roder, H.
    Oliveira, C.
    Roder, J.
    [J]. ANNALS OF ONCOLOGY, 2018, 29 : 21 - 21
  • [5] Interchangeability of anti-PD1 antibodies in patients (pts) with metastatic NSCLC
    Kravchuk, Darya
    Fedyanin, Mikhail
    Ivan, Borovkov
    Moiseenko, Fedor Vladimirovich
    Zhukova, Lyudmila
    Pokataev, Ilya
    Rays, Anastasia
    Chubenko, Viacheslav
    Volkov, Nikita
    Ivanilov, Kirill
    Glazkova, Elena
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [6] EGFR mutations are associated with unfavourable efficacy to anti-PD1 therapy in NSCLC
    Liu, S-Y.
    Dong, Z.
    Zhong, W-Z.
    Wu, Y-L.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [7] Predicting the response to anti-PD1 therapy in metastatic melanoma
    Heinzerling, Lucie
    Kirchberger, Michael Constantin
    Walter, Lisa
    Schuler, Gerold
    [J]. TRANSLATIONAL CANCER RESEARCH, 2016, 5 : S576 - S579
  • [8] Response to anti-PD1 therapy with nivolumab in metastatic sarcomas
    Paoluzzi, L.
    Cacavio, A.
    Ghesani, M.
    Karambelkar, A.
    Rapkiewicz, A.
    Weber, J.
    Rosen, G.
    [J]. CLINICAL SARCOMA RESEARCH, 2016, 6
  • [9] Acquired resistance to anti-PD1 therapy in patients with NSCLC associates with immunosuppressive T cell phenotype
    Hiltbrunner, Stefanie
    Cords, Lena
    Kasser, Sabrina
    Freiberger, Sandra N.
    Kreutzer, Susanne
    Toussaint, Nora C.
    Grob, Linda
    Opitz, Isabelle
    Messerli, Michael
    Zoche, Martin
    Soltermann, Alex
    Rechsteiner, Markus
    van den Broek, Maries
    Bodenmiller, Bernd
    Curioni-Fontecedro, Alessandra
    [J]. NATURE COMMUNICATIONS, 2023, 14 (01)
  • [10] Acquired resistance to anti-PD1 therapy in patients with NSCLC associates with immunosuppressive T cell phenotype
    Stefanie Hiltbrunner
    Lena Cords
    Sabrina Kasser
    Sandra N. Freiberger
    Susanne Kreutzer
    Nora C. Toussaint
    Linda Grob
    Isabelle Opitz
    Michael Messerli
    Martin Zoche
    Alex Soltermann
    Markus Rechsteiner
    Maries van den Broek
    Bernd Bodenmiller
    Alessandra Curioni-Fontecedro
    [J]. Nature Communications, 14
12345